Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2025 09:00 ET | Source: AnaptysBio, Inc.

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy at...
November 04, 2025 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on...
November 04, 2025 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
October 29, 2025 09:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced...
October 13, 2025 09:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
September 29, 2025 16:05 ET | Source: AnaptysBio, Inc.

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will...
September 29, 2025 16:05 ET | Source: AnaptysBio, Inc.

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it...
August 27, 2025 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
August 06, 2025 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial;...
June 03, 2025 16:05 ET | Source: AnaptysBio, Inc.

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety and tolerability, particularly...